Sydney-based Pharmaxis (ASX:PXS) has announced the first patient has been dosed in its Phase 1 clinical trial of an anti‐fibrotic Lysyl Oxidase (LOX) inhibitor focused on treating pancreatic cancer. …
Latest Video
New Stories
-
Sanofi's Karen Hood: 'Industry needs a clear and specific plan'
October 14, 2019 - - Latest News -
Government backs new cell and tissue research facility
October 14, 2019 - - Latest News -
Industry 'right in the crosshairs'
October 14, 2019 - - Latest News -
Industry prepares to gather in Canberra for PharmAus19
October 14, 2019 - - Latest News -
New Cabinet Handbook brings forward Budget process
October 14, 2019 - - Latest News -
Lundbeck and Otsuka 'on the bridge' for mental health
October 14, 2019 - - Latest News -
Cancer and malaria the focus of new CSL Centenary Fellowships
October 11, 2019 - - Latest News